Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2009

View Archived Issues

Direct antagonism of NOTCH transcriptional activity shows potent antiproliferative effects in vivo

Interim data from phase I trial of Cortiject in diabetic macular edema disclosed at ISOPT

ABT-263 shows favorable safety and PK profiles in phase I/IIa trial in CLL

Recent data suggest Ontak may enhance endogenous immunity to breast cancer antigens

Treatment with entinostat plus aromatase inhibitor is well tolerated in breast cancer

Novartis discovers novel compounds for the treatment of parasitic infections

Takeda claims glucokinase activators for the treatment of diabetes

Vitae Pharmaceuticals presents 11beta-HSD1 inhibitors for obesity therapy

The University of Utah discloses PKC activators for cancer therapy

Novel muscarinic receptor agonists in early development at Lundbeck

Pfizer's Toviaz superior to Detrol LA in treating urge urinary incontinence

FDA's ODAC recommends not approving Tarceva as first-line NSCLC therapy

InSite Vision to advance new ocular anti-inflammatory candidate ISV-303

FDA's ODAC to review ChemGenex's Omapro for chronic myeloid leukemia

Advanced Life Sciences' Restanza effective against tularemia in nonhuman primates

FDA grants orphan drug designation to Clinuvel's afamelanotide for solar urticaria

Hybrigenics to begin phase IIb efficacy trial of inecalcitol in hormone-refractory prostate cancer

BioAlliance gains French Drug Agency's approval to initiate phase II clonidine trial

Advaxis and GOG begin phase II trial of ADXS11-001 in advanced cervix cancer

ALS TDI and Applied Proteomics complete first stage of collaboration on ALS biomarkers

Syntiron grants Sanofi Pasteur exclusive worldwide license to MRSA vaccine

Nanotherapeutics acquires Oscient's ramoplanin and Epix's PRX-3140

Almac Discovery begins phase I trial of intranasal granisetron spray for CINV

Intercell reports interim data from ongoing phase II trial of P. aeruginosa vaccine

Mayo Clinic licenses molecular breast imaging technology to Gamma Medica-Ideas

Merck & Co. to acquire Avecia's biologics business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...